Development
Lexicon Pharmaceuticals, Inc.
LXRX
$1.15
$0.109.52%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | -116.04% | -82.63% | -36.03% | -19.07% | -1.15% |
| Total Depreciation and Amortization | 39.81% | 34.58% | 2.75% | -8.04% | 6.93% |
| Total Amortization of Deferred Charges | 184.79% | 77.27% | 960.00% | 4,212.50% | 1,176.47% |
| Total Other Non-Cash Items | -89.24% | 34.71% | 23.20% | 43.65% | -2.36% |
| Change in Net Operating Assets | 705.33% | 187.26% | -21.75% | 1,248.70% | -68.97% |
| Cash from Operations | -114.10% | -56.08% | -34.98% | 5.52% | -13.35% |
| Capital Expenditure | -1,975.00% | -- | -226.32% | -5,317.39% | 98.12% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 49.16% | -445.64% | 384.88% | 315.43% | -41,179.14% |
| Cash from Investing | 49.06% | -446.66% | 374.34% | 296.56% | -19,199.00% |
| Total Debt Issued | 100.40% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | 376.56% |
| Repurchase of Common Stock | -- | -- | 4.63% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -100.22% | -- | -103.54% | 320.00% | 375.30% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3,002.26% | 300.34% | -347.61% | 198.07% | -217.26% |